focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 61.50
High: 61.50
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

16 Oct 2008 07:00

RNS Number : 9607F
Oxeco PLC
16 October 2008
 



16 October 2008

Oxeco Plc (the "Company" or the "Group" )

Interim financial report for the six months ended 31 July 2008

Chairman's Statement

I am pleased to report on your Group's performance for the six months ended 31 July 2008. 

Oxeco Plc is a holding and management company, specialising in the development and growth of trading businesses within the technology and science sectors. The Company currently has one subsidiary, Oxray Ltd, which was acquired in June 2007 and is a start up business which aims to become a leading provider of molecular structure determination services to both industry and academic institutions. 

The unaudited consolidated loss before tax for the Group in six months to 31 July 2008 amounted to £105,000 compared to £3,000 for the comparable period from incorporation on 17 October 2006 to 31 July 2007. Consolidated net assets at 31 July 2008 amounted to £4.77 million including cash balances of £2.64 million versus net assets of £4.93 million and cash balances of £2.81 million a year earlier at 31 July 2007. The cash outflow for the Group during the six months to 31 July 2008 amounted to £120,000 and cash balances continue to be managed prudently, with tight cost control.

Oxray's primary objectives are the development of novel X-ray crystallography structure determination software and the provision of a small-molecule X-ray crystallography structure service. The service uses a web portal behind which the company can work to maximise the extent to which the service can be automated. The Company offers standardised response times to its customers but also offers market premium services such as a fast-response and extended scientific reporting suitable to support customers' patent applications. Oxray expects to complete the initial development of it's X-ray crystallography structure determination software within the next six months and will then focus on the marketing of the service and the establishment of a solid customer base.

Oxeco Plc is well capitalised and I am confident that your Company will continue to make considerable progress in its development during the second half of the year despite turbulent financial marketsYour Directors are continuing to evaluate a range of new commercial and acquisition opportunities which they believe fulfil the Company's original objectives of investing in the technology and science sectors, and especially those which are complimentary to the existing Group activities.

Finally I would like to conclude by thanking our employees and management for their hard work and support in the growth and development of the Group in the period.

Jussi Westergren

Executive Chairman

Contact:

Michael Bretherton

Oxeco plc

www.oxecoplc.com

+44 (0) 207352 8989

 Ray Zimmerman/Jonathan Evans

Zimmerman Adams International Limited

+44 (0) 207 060 1760

Daniel Briggs

Religare Hichens, Harrison plc

+44 (0) 207 382 7776

 

 

 

 

OXECO PLC

CONDENSED CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTHS TO 31 JULY 2008

 
Notes
Six months to 31 July
2008
(Unaudited)
Period to
31 July
2007
(Unaudited)
Period to
31 January
2008
(Audited)
 
 
£000
£000
£000
 
 
 
 
 
Revenue
 
6
-
7
Administrative expenses
 
(188)
(95)
(243)
 
 
 
 
 
Operating Loss
 
(182)
(95)
(236)
 
 
 
 
 
Interest receivable
 
77
92
178
 
 
 
 
 
Loss before tax
 
(105)
(3)
(58)
 
 
 
 
 
Taxation
2
3
(5)
 
 
 
 
 
Loss for the period
 
(102)
(3)
(63)
Earnings per share Basic and Diluted
3
(0.02p)
(0.00)p
(0.01)p
 
 

 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

The loss for the period arises from the Group's continuing operations.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS TO 31 JULY 2008

 
Share Capital £000
Share Premium £000
Retained Loss £000
Total Equity £000
At 17 October 2006
Issue of shares
600
4,500
5,100
Expenses of issue of shares
(167)
(167)
Loss for the period
(3)
(3)
At 31 July 2007
600
4,333
(3)
4,930
Loss for the period
-
-
(60)
(60)
At 31 January 2008
600
4,333
(63)
4,870
Loss for the period
-
-
(102)
(102)
At 31 July 2008
600
4,333
(165)
4,768
 
 

OXECO PLC

CONDENSED CONSOLIDATED BALANCE SHEET

AS AT 31 JULY 2008

 
Notes
31 July 2008
31 July 2007
31 January 2008
 
 
(Unaudited)
(Unaudited)
(Audited)
 
 
£000
£000
£000
ASSETS
Non-current assets
 
 
 
 
Property, plant and equipment
 
1
1
2
Intangible assets - goodwill
 
2,120
2,120
2,120
Total non-current assets
 
2,121
2,121
2,122
 
 
 
 
 
Current assets
 
 
 
 
Trade and other receivables
 
38
16
29
Cash and cash equivalents
 
2,641
2,816
2,761
Total current assets
 
2,679
2,832
2,790
 
 
 
 
 
TOTAL ASSETS
 
4,800
4,953
4,912
 
 
 
 
 
LIABILITIES
 
 
 
 
Current Liabilities
 
 
 
 
Trade and other payables
 
(30)
(23)
(37)
Current taxation
 
(2)
-
(5)
 
 
 
 
 
TOTAL LIABILITIES
 
(32)
(23)
(42)
 
 
 
 
 
NET ASSETS
 
4,768
4,930
4,870
 
 
 
 
 
EQUITY
 
 
 
 
Issued capital
3
600
600
600
Share premium
 
4,333
4,333
4,333
Revenue reserve
 
(165)
(3)
(63)
TOTAL EQUITY SHAREHOLDERS’ FUNDS
 
4,768
4,930
4,870
 
 

 

Approved by the Board and authorised for issue on 16 October 2008.

J P Westergren M A Bretherton

Chairman Finance Director

OXECO PLC

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

FOR THE SIX MONTHS ENDED 31 JULY 2008

 
Six months to
31 July 2008
Period to
31 July 2007
Period to
31 January 2008
 
(Unaudited)
(Unaudited)
(Audited)
 
£000
£000
£000
OPERATING ACTIVITIES
 
 
 
Operating loss before taxation
(182)
(95)
(236)
Depreciation of property, plant and equipment
1
-
-
Increase in trade and other receivables
(9)
(16)
(29)
Decrease in trade and other payables
(7)
(30)
(15)
Net cash outflow from operations
(197)
(141)
(280)
 
 
 
 
INVESTING ACTIVITIES
 
 
 
Purchase of property, plant and equipment
-
-
(2)
Acquisition of subsidiaries
-
(100)
(100)
Cash and bank in subsidiaries at acquisition
-
32
32
Net cash outflow from investing activities
-
(68)
(70)
 
 
 
 
FINANCING ACTIVITIES
 
 
 
Proceeds from issue of share capital
-
3,100
3,100
Expenses of issue of share capital
-
(167)
(167)
Interest received
77
92
178
Net cash inflow from financing activities
77
3,025
3,111
 
 
 
 
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS
(120)
2,816
2,761
 
 
 
 
Cash and cash equivalents at start of period
2,761
-
 
 
 
 
CASH AND CASH EQUIVALENTS AT END OF PERIOD
2,641
2,816
2,761
 
 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

OXECO PLC

NOTES TO THE CONDENSED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED 31 JULY 2008

1) SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

The interim financial statements of Oxeco Plc are unaudited condensed consolidated financial statements for the period for the six months period to 31 July 2008. These include unaudited comparatives for the period from incorporation on 1October 2006 to 31 July 2007 together with audited comparatives for the period from incorporation on 17 October 2006 to 31 July 2007.

The condensed consolidated financial statements have been prepared under the historic cost convention and incorporate the financials of Oxeco Plc for the period and its subsidiary undertaking from the date of acquisition.

The accounting policies adopted are consistent with those followed in the preparation of the Group's annual financial statements for the period ended 31 January 2008.

The condensed consolidated financial statements do not constitute statutory accounts. The statutory accounts for the period to 31 January 2008 have been reported on by the Company's auditors and have been filed with the Registrar of Companies. The report of the auditors was unqualified and did not contain a statement under section 237(2) or 237(3) of the Companies Act 1985.

2) TAXATION

The accrued tax charge for the six month period is based on an estimated effective tax rate of nil, after allowance for utilisation of tax losses brought forward in subsidiaries and prior year adjustments, (period to 31 July 2007: effective tax rate nil, period to 31 January 2008: effective tax rate 8.6 per cent.).

3) LOSS PER SHARE

Basic loss per share is based on the net loss for the period of £102,000 attributable to equity holders of the parent divided by the weighted average number of ordinary shares in issue during the period of 600,000,000, (period to 31 July 2007: loss £3,000 divided by the weighted average number of 353,658,537 shares; period to 31 January 2008: loss £63,000 divided by the weighted average of 456,050,955 shares). Fully diluted earnings per share are the same as basic earnings per share.

4) SHARE CAPITAL
Number
£’000
Authorised ordinary shares of 1p:
 
 
 
 
 
At 31 July 2007, 31 January 2008 and 31 July 2008
1,000,000,000
1,000
 
 
 
Allotted, issued and fully paid ordinary shares of 1p:
 
 
 
 
 
At 31 July 2007, 31 January 2008 and 31 July 2008
600,000,000
600
 
 

5) RELATED PARTY TRANSACTIONS

During the period the Company entered into the following transactions with Ora Capital Partners Plc (ORA) which as at 31 July 2008 held 45.25% of the Company's issued share capital.

 
Six months to
31 July
 2008
Period to
31 July
2007
Period to
31 January 2008
 
(Unaudited)
(Unaudited)
(Audited)
 
£000
£000
£000
Management consultancy fees charged by ORA
6
7
18
 

 

During the period the Company's wholly owned subsidiary, Oxray Ltd, borrowed £nil (31 July 2007: £100,000)  from the Company for working capital purposes. The loan is non-interest bearing, is repayable on demand and the outstanding balance at 31 July 2008 was £200,000 (31 July 2007: £100,000).

6) INTERIM FINANCIAL REPORT

A copy of this interim report will be distributed to shareholders and is also available on the Company's website at www.oxecoplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR ILFLDISLELIT
Date   Source Headline
14th Feb 20137:00 amRNSSuccessful safety study of dCELL® Meniscus
11th Feb 20132:57 pmRNSDirectorate Change
9th Jan 20137:15 amRNSHolding(s) in Company
30th Nov 201211:21 amRNSTissue Regenix board changes
26th Nov 20127:00 amRNSSets up US subsidiary
19th Nov 20127:00 amRNSAdds new patent global licence portfolio
4th Oct 20127:00 amRNSInterim data from clinical trial of dCELL® Dermis
4th Oct 20127:00 amRNSHalf Yearly Report
1st Oct 201210:57 amRNSTissue Regenix - senior development appointment
28th Sep 20123:30 pmRNSNotice of Results
7th Sep 20127:00 amRNSdCELL(R) vascular patch is safe and effective
2nd Aug 20122:31 pmRNSTissue Regenix makes appointment to Cardiac team
31st Jul 20123:02 pmRNSDirector/PDMR Shareholding
19th Jun 20122:39 pmRNSHolding(s) in Company
14th Jun 20127:00 amRNSResearch Update
11th Jun 201212:35 pmRNSResult of AGM
25th May 20127:00 amRNSExpands scope of development activities with NHSBT
10th May 20127:00 amRNSFinal Results
19th Apr 20121:49 pmRNSPoster shown at SAWC
16th Apr 20123:18 pmRNSNotice of Results
7th Feb 20124:00 pmRNSIssue of Equity and Total Voting Rights
11th Jan 201211:36 amRNSHolding(s) in Company
6th Jan 20125:05 pmRNSHolding(s) in Company
3rd Jan 20125:45 pmRNSHolding(s) in Company
3rd Jan 20125:43 pmRNSHolding(s) in Company
3rd Jan 20128:49 amRNSHolding(s) in Company
28th Dec 201112:00 pmRNSResult of General Meeting
8th Dec 201112:53 pmRNSIssue of Equity
25th Nov 20112:23 pmRNSUniversity Partner wins Queen's Anniversary Prize
4th Nov 20112:16 pmRNSHolding(s) in Company
14th Oct 20112:33 pmRNSHolding(s) in Company
10th Oct 20117:00 amRNSHalf Yearly Report
26th Jul 201111:04 amRNSIssue of Equity
7th Jul 20113:52 pmRNSIssue of Share Options
5th Jul 20111:30 pmRNSIssue of Equity
22nd Jun 20118:35 amRNSReceives EUR280,000 Grant Funding
13th Jun 20117:00 amRNSDirectorate Appointment
3rd Jun 201110:02 amRNSAGM Statement
11th May 20117:00 amRNSPositive Results in Clinical Evaluation of dCELL
4th May 20117:00 amRNSFinal Results
21st Apr 20117:00 amRNSTissue Regenix enters commercialisation agreement
29th Mar 20117:00 amRNSDirectorate Change
10th Mar 20117:00 amRNSNotice of allowance of patent received
4th Jan 201111:27 amRNSHolding(s) in Company
30th Dec 20109:05 amRNSHolding(s) in Company
23rd Dec 201012:44 pmRNSChange of Adviser
21st Dec 201010:12 amRNSAdviser - Change of Name
16th Dec 20107:00 amRNSResearch Update
10th Dec 20109:20 amRNSChange of Adviser
26th Nov 20103:12 pmRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.